The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Detection of circulating tumor DNA in pancreas cancer.
 
Daniel King
No Relationships to Disclose
 
Ash A. Alizadeh
Leadership - Lymphoma Research Foundation; Lymphoma Research Foundation; Lymphoma Research Foundation; Lymphoma Research Foundation
Stock and Other Ownership Interests - CAPP Medical; CAPP Medical; CAPP Medical; CAPP Medical; CiberMed; CiberMed; CiberMed; CiberMed; Forty Seven; Forty Seven; Forty Seven; Forty Seven
Honoraria - Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Roche; Roche; Roche; Roche
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Celgene; Celgene; Celgene; Celgene
Patents, Royalties, Other Intellectual Property - Patent filings on ctDNA detection, assigned to Stanford University. (Inst); Patent filings on ctDNA detection, assigned to Stanford University. (Inst); Patent filings on ctDNA detection, assigned to Stanford University. (Inst); Patent filings on ctDNA detection, assigned to Stanford University. (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Roche; Roche; Roche; Roche
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I); Seagen (I); Seagen (I); Seagen (I)
Honoraria - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Forty Seven; Forty Seven; Forty Seven; Forty Seven; Genentech; Genentech; Genentech; Genentech; Incyte; Incyte; Incyte; Incyte; Merck; Merck; Merck; Merck; Newlink Genetics; Newlink Genetics; Newlink Genetics; Newlink Genetics
Consulting or Advisory Role - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Forty Seven; Forty Seven; Forty Seven; Forty Seven; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Incyte; Incyte; Incyte; Incyte; ipsen; ipsen; ipsen; ipsen; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Merck; Merck; Merck; Merck; Newlink Genetics; Newlink Genetics; Newlink Genetics; Newlink Genetics
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Forty seven (Inst); Forty seven (Inst); Forty seven (Inst); Forty seven (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme